As a Barclays analyst put it, it’s been a “slow-moving car crash”. Early supply shortages pushed patients to competitors, while Novo’s cautious marketing lagged behind Lilly’s aggressive, ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS ...

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

Novo Nordisk shares fell significantly due to pressure from U.S. President Donald Trump to cut drug prices, and competition ...

The Trump administration is contemplating a pilot program to cover weight-loss drugs under Medicare and Medicaid. The ...

Medicare and Medicaid could expand coverage of GLP-1 drugs, such as Ozempic and Wegovy, and pay for patients’ use of the ...

Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...

Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...